Literature DB >> 24561793

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages.

Paolo Giannoni1, Gabriella Pietra1, Giorgia Travaini2, Rodolfo Quarto1, Genti Shyti1, Roberto Benelli3, Laura Ottaggio4, Maria Cristina Mingari5, Simona Zupo4, Giovanna Cutrona4, Ivana Pierri6, Enrico Balleari7, Alessandra Pattarozzi8, Marco Calvaruso9, Claudio Tripodo9, Manlio Ferrarini10, Daniela de Totero11.   

Abstract

Hepatocyte growth factor, produced by stromal and follicular dendritic cells, and present at high concentrations in the sera of patients with chronic lymphocytic leukemia, prolongs the survival of leukemic B cells by interacting with their receptor, c-MET. It is, however, unknown whether hepatocyte growth factor influences microenvironmental cells, such as nurse-like cells, which deliver survival signals to the leukemic clone. We evaluated the expression of c-MET on nurse-like cells and monocytes from patients with chronic lymphocytic leukemia and searched for phenotypic/functional features supposed to be influenced by the hepatocyte growth factor/c-MET interaction. c-MET is expressed at high levels on nurse-like cells and at significantly higher levels than normal on monocytes from patients. Moreover, the hepatocyte growth factor/c-MET interaction activates STAT3(TYR705) phosphorylation in nurse-like cells. Indoleamine 2,3-dioxygenase, an enzyme modulating T-cell proliferation and induced on normal monocytes after hepatocyte growth factor treatment, was detected together with interleukin-10 on nurse-like cells, and on freshly-prepared patients' monocytes. Immunohistochemical/immunostaining analyses demonstrated the presence of c-MET(+) and indoleamine 2,3-dioxygenase(+) cells in lymph node biopsies, co-expressed with CD68 and vimentin. Furthermore nurse-like cells and chronic lymphocytic monocytes significantly inhibited T-cell proliferation, prevented by anti-transforming growth factor beta and interleukin-10 antibodies and indoleamine 2,3-dioxygenase inhibitors, and supported CD4(+)CD25(high+)/FOXP3(+) T regulatory cell expansion. We suggest that nurse-like cells display features of immunosuppressive type 2 macrophages: higher hepatocyte growth factor levels, produced by leukemic or other microenvironmental surrounding cells, may cooperate to induce M2 polarization. Hepatocyte growth factor may thus have a dual pathophysiological role: directly through enhancement of survival of the leukemic clone and indirectly by favoring T-cell immunosuppression. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24561793      PMCID: PMC4040912          DOI: 10.3324/haematol.2013.091405

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  50 in total

1.  Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.

Authors:  Daniela de Totero; Raffaella Meazza; Simona Zupo; Giovanna Cutrona; Serena Matis; Monica Colombo; Enrico Balleari; Ivana Pierri; Marina Fabbi; Matteo Capaia; Bruno Azzarone; Marco Gobbi; Manlio Ferrarini; Silvano Ferrini
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

2.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

3.  Nurse-like cells show deregulated expression of genes involved in immunocompetence.

Authors:  Nupur Bhattacharya; Susanne Diener; Irina S Idler; Judith Rauen; Sarah Häbe; Hauke Busch; Annett Habermann; Thorsten Zenz; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Br J Haematol       Date:  2011-05-25       Impact factor: 6.998

4.  Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.

Authors:  A E Loercher; M A Nash; J J Kavanagh; C D Platsoucas; R S Freedman
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

5.  Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells.

Authors:  Alessandro Poggi; Claudia Prevosto; Silvia Catellani; Ilaria Rocco; Anna Garuti; Maria R Zocchi
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

6.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

7.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

Review 8.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  The Met tyrosine kinase receptor in development and cancer.

Authors:  Alessandra Gentile; Livio Trusolino; Paolo M Comoglio
Journal:  Cancer Metastasis Rev       Date:  2008-03       Impact factor: 9.264

Review 10.  Transforming growth factor-beta regulation of immune responses.

Authors:  Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  21 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.

Authors:  M Qorraj; H Bruns; M Böttcher; L Weigand; D Saul; A Mackensen; R Jitschin; D Mougiakakos
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 4.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 5.  MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech.

Authors:  Chiara Cioccarelli; Barbara Molon
Journal:  Clin Exp Immunol       Date:  2022-06-11       Impact factor: 5.732

Review 6.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

7.  Reprogramming Nurse-like Cells with Interferon γ to Interrupt Chronic Lymphocytic Leukemia Cell Survival.

Authors:  Shalini Gautam; Kavin Fatehchand; Saranya Elavazhagan; Brenda F Reader; Li Ren; Xiaokui Mo; John C Byrd; Susheela Tridandapani; Jonathan P Butchar
Journal:  J Biol Chem       Date:  2016-05-13       Impact factor: 5.157

8.  Conservation of Intracellular Pathogenic Strategy among Distantly Related Cryptococcal Species.

Authors:  Joudeh B Freij; Man Shun Fu; Carlos M De Leon Rodriguez; Amanda Dziedzic; Anne E Jedlicka; Quigly Dragotakes; Diego C P Rossi; Eric H Jung; Carolina Coelho; Arturo Casadevall
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

Review 9.  Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.

Authors:  Rossana Maffei; Stefania Fiorcari; Silvia Martinelli; Leonardo Potenza; Mario Luppi; Roberto Marasca
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.